Three critical drugs to watch now
OptumRx Insights Report: What’s coming for the rest of 2020
OptumRx actively monitors the drug development pipeline. In this latest edition, we are highlighting the three drugs we expect to make the biggest impact this year along with a few critical larger trends to watch.
"As noted in the Q1 2020 issue of this report, we expect the emphasis on orphan drugs to continue this year, making up nearly 40% of newly approved drugs across all disease categories...we now are starting to see the development of orphan drugs become more competitive, increasing the potential for reduced costs and broader patient accessibility." - Sumit Dutta, OptumRx Chief Medical Officer
Don't want to read the full report? Download the brief summary.